A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in EuropeReportar como inadecuado




A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

(2014)INFECTION.42(4).p.757-762 Mark abstract ATRIPLA is licensed for use only in HIV-positive persons whose viral loads < 50 for a parts per thousand yen3 months. We investigated the use of ATRIPLA as first-line antiretroviral therapy (ART) in EuroSIDA using a web-based survey performed in Autumn 2012. 96/112 clinics (85.7 %) completed the survey. Recommendations when initiating first-line ART was TRUVADA plus efavirenz in 36 (37.5 %), ATRIPLA in 35 (36.5 %), a different first-line regimen in 12 clinics (12.5 %), and no recommendation in 7 clinics (7.3 %). ATRIPLA was commonest in Northern (15/21 clinics; 71.4 %), and least common in Eastern Europe (2/31 clinics; 6.5 %; p < 0.0001). Over one-third of the participating clinics in this survey were using ATRIPLA as first-line antiretroviral therapy, despite EMA recommendations.

Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-5913705



Autor: A Mocroft, P Reiss, A Rakhmanova, D Banhegyi, AN Phillips, S De Wit, M Ristola, JD Lundgren, J Grarup, O Kirk, et al.

Fuente: https://biblio.ugent.be/publication/5913705



DESCARGAR PDF




Documentos relacionados